SynthesisPloS one2018
Accuracy of rapid diagnosis of Talaromyces marneffei: A systematic review and meta-analysis.
Synthesis in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Burden of Talaromyces marneffei infection in people living with HIV/AIDS in Asia during ART era: a systematic review and meta-analysis.BMC infectious diseases · 2020Pooled it
- An Interpretable Machine Learning Model for Predicting the Presence of Talaromycosis in HIV Patients Lacking Skin Lesions.Mycopathologia · 2026Article
- Clinical Characteristics and Prognosis of AIDS Complicated with Talaromycosis marneffei Infection: a Single-Center Retrospective Study.Infectious diseases and therapy · 2025Article
- Advancements in Diagnosing Talaromycosis: Exploring Novel Strategies and Emerging Technologies.Journal of fungi (Basel, Switzerland) · 2025Review
- Optimization and clinical evaluation of a 5.8S rRNA quantitative PCR assay for the diagnosis of talaromycosis.Medical mycology · 2025Article
- Metagenomic Next-Generation Sequencing Unravels Talaromyces Marneffei-Induced Bone Destruction in an HIV-Negative Woman: A Case Report with Fatal Outcome.Infection and drug resistance · 2025Article
- Machine learning-based high-specificity diagnostic model forFrontiers in microbiology · 2025Article
- An overview of rapid non-culture-based techniques in various clinical specimens for the laboratory diagnosis ofFrontiers in cellular and infection microbiology · 2025Review
- A web-based dynamic nomogram for estimating talaromycosis risk in hospitalized HIV-positive patients.Epidemiology and infection · 2024Article
- Risk factors and prediction model for mortality in HIV/Talaromyces marneffei co-infection: A retrospective cohort study.Heliyon · 2024Article
- Genomic Sequence Resource ofJournal of fungi (Basel, Switzerland) · 2023Article
- An Overview of Diagnostic and Management Strategies for Talaromycosis, an Underrated Disease.Journal of fungi (Basel, Switzerland) · 2023Review
- An Overlooked and Underrated Endemic Mycosis-Talaromycosis and the Pathogenic Fungus Talaromyces marneffei.Clinical microbiology reviews · 2023Review
- UnusualFrontiers in immunology · 2023Review
- Case report: Diagnosis ofFrontiers in cellular and infection microbiology · 2023Article
- Molecular Diagnosis of Endemic Mycoses.Journal of fungi (Basel, Switzerland) · 2022Review
- Immunologic Diagnosis of Endemic Mycoses.Journal of fungi (Basel, Switzerland) · 2022Review
- Talaromyces marneffei Mp1p Antigen Detection may Play an Important Role in the Early Diagnosis of Talaromycosis in Patients with Acquired Immunodeficiency Syndrome.Mycopathologia · 2022Article
- Characteristics and Prognosis of Talaromyces marneffei Infection in HIV-positive Children in Southern China.Mycopathologia · 2022Review
- Diagnosis by metagenomic next-generation sequencing of aFrontiers in pediatrics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo examine the accuracy of Rapid Diagnosis of Talaromyces marneffei (RDTM) in order to improve diagnosis and treatment for clinical measures and reduce the mortality due to associated infections.
methodsIn this systematic review and meta-analysis, we screened PubMed, Ovid (Cochrane library) and Web of Science, Chinese database CNKI and Wanfang for articles published between 1956 and December, 2017. Data were taken from cross-sectional studies as well as from baseline measurements in longitudinal studies with clinical follow-up. Articles were excluded if they did not contain a cohort with T. marneffei and a control cohort or a cohort with standard fungus culture. Data were extracted by two authors and checked by three for accuracy. For quality assessment, modified QUADAS-2 criteria were used.
resultsThe 26 included diagnostic studies enrolled 5,594 objectives in 632 patients with T. marneffei infections and 2,612 negative controls between 1996 and 2017 in Thailand, Vietnam and China. The total combined sensitivity and specificity of rapid diagnosis of T. marneffei was 0.82 (95% CI: 0.68-0.90) and 0.99 (95% CI: 0.98-1.00). According to the experimental method, the included studies can be divided into three subgroups, including PCR-based, ELISA-based and others. The results showed these three subgroups had a highly pooled specificity of 1.00 (95% CI: 0.99-1.00), 0.99 (0.98-1.00) and 0.97 (95% CI: 0.91-1.00), respectively, while combined sensitivity was 0.84 (95% CI: 0.37-0.98), 0.82 (95% CI: 0.64-0.92) and 0.77 (95% CI: 0.54-0.91), respectively.
conclusionsAlthough serological methods with a high specificity is essential for potential rapid diagnostic, false-negative results can be obtained in the serum samples, there is no suitable rapid serological test to refer to as is the case with TM infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.